Metastatic uveal melanoma remains a lethal disease with limited therapeutic options. Building on the SCANDIUM clinical trial program, which has demonstrated that locoregional hepatic perfusion can enhance immunogenicity and improve outcomes when combined with checkpoint inhibitors, the SCANDIUM-III trial will evaluate minimally invasive percutaneous hepatic perfusion together with ipilimumab and nivolumab in a national, randomized setting. To overcome the current lack of predictive and prognostic biomarkers, we will perform an integrated, multimodal precision-medicine analysis of both tumor tissue and longitudinal blood samples. Tumor profiling will include whole-genome sequencing, RNA sequencing, and spatial transcriptomics/proteomics, while serial liquid biopsies will undergo ctDNA sequencing, proteomic, and metabolomic analysis. These high-dimensional datasets will be used to identify determinants of treatment response, resistance, and survival across SCANDIUM, SCANDIUM-II, and SCANDIUM-III. The computational demands of processing, these large-scale multi-omic and spatial datasets require access to high-performance computing resources. This application is specifically for analysis of spatial transcriptomic/proteomic data within this project.